Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVX-CoV2373 Booster in Adults Previously Vaccinated With BBIBP-CorV
NCT05249816Phase 3Completed
- Sponsor
- Cogna Technology Solutions
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cogna Technology Solutions. Primary endpoints: Ratio of IgG Geometric Mean Titers at Day 14, Difference in Seroconversion Rates at Day 14 and 3 more. Started Mar 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05249816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249816.